triazoles has been researched along with Dyslipidemia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bouslama, R; Chi, NW; Dumont, V; Krauss, S; Kuusela, S; Lehtonen, S; Linden, AM; Pirinen, E; Ramadan, UA; Rinnankoski-Tuikka, R; Waaler, J; Wang, H | 1 |
| Babu, MH; Gaikwad, AN; Gupta, A; Kumar, D; Puri, S; Rajan, S; Reddy, MS; Shankar, K; Srivastava, A; Varshney, S | 1 |
| Anderson, MS; Engel, SS; Hanson, ME; Musliner, T; Steinberg, H | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
| Guan, M; Li, C; Li, J; Lyv, F; Wang, C; Xue, Y; Zeng, Y; Zheng, Z | 1 |
| Charest, A; Couture, P; Droit, A; Kelly, I; Lamarche, B; Lépine, MC; Tremblay, AJ | 1 |
| Kim, JB; Mahdavi, H; Navab, M; Safarpour, S; Tien, DA | 1 |
| Aliev, DA; Azizov, VA; Musaev, IN; Sadygova, TA; Zeĭnalov, RS | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Bellido, R; Bonjoch, A; Casadellà, M; Clotet, B; Negredo, E; Noguera-Julian, M; Paredes, R; Pérez-Álvarez, N; Pou, C; Puig, J | 1 |
| Feng, Y; Howard, AD; Li, C; Li, Z; Moller, DE; Mu, J; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K | 1 |
2 review(s) available for triazoles and Dyslipidemia
| Article | Year |
|---|---|
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Topics: Biomarkers; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Lipids; Pyrazines; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
5 trial(s) available for triazoles and Dyslipidemia
| Article | Year |
|---|---|
Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes.
Topics: Apolipoprotein B-48; Apolipoproteins; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Triglycerides | 2014 |
[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, LDL; Dyslipidemias; Estrogen Antagonists; Female; Humans; Letrozole; Lipid Metabolism Disorders; Nitriles; Tamoxifen; Time Factors; Toremifene; Triazoles; Triglycerides | 2009 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Dyslipidemias; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Hypolipidemic Agents; Intention to Treat Analysis; Male; Maraviroc; Middle Aged; Pilot Projects; Prospective Studies; Triazoles; Triglycerides; Viral Tropism | 2013 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles | 2007 |
5 other study(ies) available for triazoles and Dyslipidemia
| Article | Year |
|---|---|
Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1α PARylation in db/db mice.
Topics: Abdominal Fat; Adipose Tissue, White; Animals; Body Weight; Diabetes Mellitus, Type 2; Dyslipidemias; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Poly ADP Ribosylation; Sulfones; Tankyrases; Triazoles | 2020 |
Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway.
Topics: 3T3-L1 Cells; Adipogenesis; Animals; Biological Transport; Cholesterol; Cricetinae; Drug Design; Dyslipidemias; Humans; Indoles; Mice; Structure-Activity Relationship; Triazoles; Wnt Signaling Pathway; Wnt3A Protein | 2018 |
The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice.
Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Dipeptidyl-Peptidase IV Inhibitors; Dyslipidemias; Fibronectins; Kidney; Male; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Sitagliptin Phosphate; Transforming Growth Factor beta1; Triazoles | 2014 |
Dyslipidemia and cardiovascular diseases.
Topics: Benzimidazoles; Cardiovascular Diseases; Dyslipidemias; Humans; Lipoproteins, HDL; Niacin; Propionates; Triazoles | 2009 |
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Disease Models, Animal; Dyslipidemias; Glipizide; Hypoglycemic Agents; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred ICR; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2006 |